Results 21 to 27 of about 29 (27)

The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models

Journal of Pharmacology and Experimental Therapeutics, 2016
Kazunori Suzuki, Haruhide Kimura
exaly  

TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms

Neuropsychopharmacology, 2016
Kazunori Suzuki, Haruhide Kimura
exaly  

A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD

Journal of Attention Disorders
Graeme A E Donnelly, Daniel J Cox
exaly  

Catabolism of very low density lipoproteins in the rabbit effect of changing composition and pool size

Lipids and Lipid Metabolism, 1978
exaly  

Patent Reviews: Re28,162; 3,884,553; 3,977,778; 4,025,180; 4,050,788; 4,056,307; 4,056,308; 4,062,629; 4,063,805; 4,063,806; 4,065,208; 4,066,335; 4,066,339; 4,067,646; 4,068,932; 4,070,097; 4,073,579; 4,078,169; 4,095,899; 4,078,856; 4,078,858; 4,081,672; 4,088,389; 4,092,060; 4,095,900; 4,096,387; 4,096,407; 4,097,749

Applied Optics, 1979
exaly  

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

Expert Opinion on Investigational Drugs, 2009
exaly  

Pre‐clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK‐063

Basic and Clinical Pharmacology and Toxicology, 2018
exaly